Introduction/Objective. The aim of this study was to evaluate the outcome of corneal collagen crosslinking (CXL) in patients with progressive keratoconus. Methods. This retrospective single-centered interventional study included 52 eyes of 41 patients who underwent epithelium-off CXL procedure at the age > 18 years. Corneal tomography data, uncorrected, and best spectacle-corrected distant visual acuity (UDVA and CDVA, respectively) were analyzed at baseline and postoperatively over the initial 12-month period. In addition, the natural course of corneal tomographic changes was demonstrated at one, three, six, nine, and 12 months after the CXL procedure. Results. At one year, mean UDVA improved significantly from 0.15 ? 0.22 (0.3 min ? logMAR ? 0 max logMAR) at baseline to 0.06 ? 0.09 logarithm of minimum angle resolution (logMAR) (0.1 min logMAR ? 0 max logMAR) (p = 0.024). Mean CDVA was 0.45 ? 0.39 0.45 ? 0.39 logMAR (0.8 min logMAR ? 0 max logMAR) at baseline and 0.06 ? 0.13 logMAR (1 min logMAR ? 0 max logMAR) at one year (p = 0.039). Maximum keratometry showed a significant flattening of 1.36 D ? 1.53 D (p = 0.0032) at one year after CXL. Minimum keratometry significantly decreased with a mean change of 1.15 ? 1.20 (p = 0.011). Mean anterior and posterior best fit sphere (ABFS and PBFS, respectively) remained stable during the entire follow-up period. Mean reduction of corneal thickness after CXL was 47 ? 61 ?m (p = 0.003). At one year, 29 (56%) eyes showed K max regression, 22 (53%) showed stabilization, and one (2%) showed progression. Spearman correlation coefficients were calculated to assess the correlation between difference in preoperative corneal thickness (CT), in posterior elevation corneal thickness (PECT), and minimum corneal thickness, ?CT (PECT ? minCT) and radius difference ?r (r1-r2). Spearman rs > 0.3 proved statistical significance and correlation. Conclusion. In our study, CXL effectively prevented progression of keratoconus in 98% of eyes at one year, while improving visual acuity. The effect of CXL can be evaluated at the earliest after six months; at that time, the stability of the corneal shape was provided by following the CXL procedure. The main limitation of this study is the small number of patients included.

Background/Objectives: Clinical differentiation between Parkinson’s disease (PD) and atypical parkinsonism (AP) remains complex. Current diagnostic procedures helpful in their distinction lack specificity, making non-invasive tools like optical coherence tomography (OCT) crucial in evaluating possible retinal changes as potential biomarkers. Our study examined the thickness of the ganglion cell inner plexiform layer complex (GCIPL), peripapillary retinal nerve fiber layer (RNFL) and macular segments in individuals with PD, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and healthy controls (HC). The objective of our study was to determine if OCT analyses can effectively discriminate PD patients from HC and whether retinal thickness can distinguish typical PD patients from those with AP. Methods: Research was an observational, cross-sectional study. Multiple retinal layers measured with OCT of PD and AP patients were compared with age- and sex-matched HC. An intergroup assessment was conducted. Results: Patients with PD and PSP exhibit a thinner GCIPL compared to HC, with no difference observed in the MSA group. GCIPL thickness between investigational groups does not differentiate between PD and AP. The RNFL and central macula thickness were statistically significantly reduced in all patient groups compared to HC. The RNFL was thinner in PSP compared to PD. Nearly all inner and outer macular segments were thinner in the investigational groups compared to HC. The preservation of outer nasal segments distinguished HC from both typical and AP. Patients with PSP and PD differed in the thickness of all macular segments, being thinner in PSP patients. Conclusions: Thickness of multiple retinal layers and macular regions might serve as a distinguishing feature between PD, AP and HC.

Diabetic retinopathy (DR) is the most frequent microvascular complication of diabetes mellitus (DM) and remains a leading cause of preventable blindness in the working-age population. Its course is notoriously variable: some patients with long-standing, poorly controlled diabetes never develop sight-threatening disease, whereas others progress rapidly despite reasonable metabolic control. This clinical heterogeneity, which the traditional risk factors cannot fully explain, has directed attention towards the inherited component of susceptibility. This review summarizes current understanding of the genetic architecture of DR, with particular emphasis on three extensively studied candidate genes: the vascular endothelial growth factor A gene (VEGFA), the angiotensin-converting enzyme gene (ACE) and the apolipoprotein E gene (APOE), specifically their most investigated polymorphisms: VEGFA rs699947, rs2010963 and rs3025039; ACE rs1799752 I/D; and APOE rs429358 and rs7412 (ε2/ε3/ε4). The evidence linking individual polymorphisms to disease is examined alongside the picture emerging from genome-wide association studies (GWAS), and the persistent inconsistency among studies is discussed in the context of ethnic differences, phenotype definition and limited statistical power. Finally, the review considers how genetic insight is beginning to inform therapy, from the established anti-VEGF paradigm to genebased approaches now in clinical trials, and outlines the main obstacles that still separate genetic findings from routine clinical use.

Reported tetracaine allergy, particularly in the absence of supporting medical documentation or a confirmed allergy diagnosis, represents a common challenge during the preoperative assessment of patients undergoing cataract surgery. In such cases, clinical decisions often rely primarily on patient history, which may be incomplete, inaccurate, or unreliable, resulting in considerable diagnostic uncertainty. A narrative review of the literature was conducted to examine the clinical relevance of reported tetracaine allergy in perioperative management of cataract surgery. Based on critical appraisal and synthesis of the available evidence, a phenotype-based framework comprising three clinical presentation phenotypes was developed, accompanied by a structured algorithm to support preoperative decision-making. The proposed framework classifies patients into three clinically relevant phenotypes: the irritative phenotype, the suspected hypersensitivity phenotype, and the clinical uncertainty phenotype. This classification provides a structured approach to interpreting reported tetracaine allergy and forms the basis of a practical algorithm for phenotype-guided preoperative management. The phenotype-based framework is intended to support, rather than replace, clinical judgment in the preoperative evaluation of patients with reported tetracaine allergy. By providing a structured approach to decision-making when diagnostic information is limited or uncertain, the framework may improve the consistency and transparency of perioperative management. Although conceptual, the proposed framework highlights the importance of obtaining reliable clinical information in patients reporting tetracaine allergy. Further methodological studies, including prospective validation, are required before the framework can be recommended for routine clinical practice.

The aim of this study was to evaluate tear cytokine and chemokine profiles in keratoconus (KC) and to assess their association with long-term tomographic outcomes after corneal collagen cross-linking (CXL). In this cross-sectional observational study, 30 KC eyes and nine healthy controls were enrolled. KC severity was graded using the modified Amsler–Krumeich classification. Tear samples were collected and analyzed using multiplex bead-based immunoassays (LEGENDplex™) for cytokines, chemokines, and TGF-β1. Patients were followed for five years after CXL. Treatment response was categorized according to corneal flattening (3 D). Individual cytokine levels showed no major differences between the KC and controls, although IL-6 and MCP-1 tended to be higher in the KC group. However, IP 10 and IL-17 were higher in controls (p < 0.05). In contrast, multiple pro-/anti-inflammatory ratios (TNF/TGF-β1, IL-17/IL-10, MCP-1/IL-10, IL-6/IL-10, IL-8/TGF-β1, MCP-1/TGF-β1, IL-6/TGF-β1, and IL-8/IL-10) were significantly elevated in the KC group (p < 0.05), indicating immune imbalance. After five years, all treated eyes remained stable or flattened. Lower baseline MCP-1 and IL-8 levels correlated with greater postoperative corneal flattening (p < 0.05). Keratoconus is characterized by disturbed tear immune homeostasis rather than isolated cytokine elevation. Lower preoperative inflammatory activity may predict a more favorable biomechanical response to CXL, supporting the potential role of tear cytokine profiling in patient stratification and prognostication.

Background: Penetrating keratoplasty (PK) is a technically demanding corneal transplant procedure frequently performed in elderly patients with substantial systemic comorbidities. In this population, an anesthetic strategy that ensures hemodynamic stability, cooperative sedation, adequate analgesia, and preserved spontaneous ventilation is highly desirable. Dexmedetomidine, a highly selective alpha2-adrenergic agonist, provides “cooperative” sedation with minimal risk of respiratory depression and additional sympatholytic benefits. Methods: This single-center retrospective observational case series included 50 consecutive patients (American Society of Anesthesiologists [ASA] II–III, age 50–90 years) undergoing PK under sub-Tenon block combined with continuous dexmedetomidine infusion. Dexmedetomidine was administered without a loading bolus at 0.7 mcg/kg/h for 10–15 min, then reduced to 0.5 mcg/kg/h, targeting a Ramsay Sedation Scale (RSS) score of 2–3. The sub-Tenon block was performed using a mixture of levobupivacaine 0.5% and lidocaine 2% (3–5 mL). Heart rate (HR), mean arterial pressure (MAP), oxygen saturation (SpO₂) and RSS were recorded in nine predefined perioperative phases. Data were analyzed descriptively. Results: The mean age was 72 ± 9 years; 52% of patients were ASA III. Hypertension was present in all patients; 30% had cardiovascular disease, 28% diabetes mellitus type II, and 30% chronic obstructive pulmonary disease. Progressive, controlled bradycardia was observed (mean HR decreased from 76 to 57 beats/min during graft transplantation), while MAP gradually decreased from hypertensive baseline values (150–160 mmHg) to an optimal intraoperative range of 115–130 mmHg, without episodes of clinically significant hypotension. SpO₂ remained stable at 98–99% throughout all phases, with no episodes of desaturation or need for airway intervention or supplemental oxygen. Target sedation (RSS 2–3) was achieved in all patients (median RSS 3), with preserved spontaneous breathing and cooperation. Sub-Tenon block-related bulging occurred in 6% of cases. No episodes of clinically significant bradycardia, malignant arrhythmia, respiratory compromise, or need to discontinue dexmedetomidine were recorded. No opioids or non-steroidal analgesics were required intraoperatively or in the early postoperative period. Conclusions: The combination of sub-Tenon block and continuous dexmedetomidine sedation without a loading bolus represents a hemodynamically stable and respiratory-safe anesthetic strategy for PK in elderly, high-risk patients. These preliminary, hypothesis-generating findings suggest that the protocol provides stable surgical conditions and a favorable safety profile, justifying future prospective randomized controlled trials to establish its comparative efficacy against general anesthesia or standard sedative regimens.